Breaking News, Financial News

Financial Report: Novartis 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis 3Q Revenues: $10.7 billion (+12%) 3Q Earnings: $2.1 billion (+32%) YTD Revenues: $31.4 billion (+12%) YTD Earnings: $6.7 billion (+19%) Comments: Pharmaceutical sales were $6.7 billion in the quarter, up 14% (9% in local currencies). Growth was driven by the oncology and cardiovascular franchises as well as $800 million in sales from recently launched products, Lucentis, Aclasta/Reclast, Exforge, Tekturna/Rasilez, Exjade and Exelon Patch. Oncology sale...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters